论文部分内容阅读
目的：为探讨ｂｃｌ－２和Ｐ１６基因蛋白在膀胱癌的表达及其临床、病理意义与预后的关系。方法：采用免疫组化技术ＳＡＢＣ法对５１例膀胱癌组织和５例正常膀胱粘膜行原癌基因ｂｃｌ－２和抑癌基因Ｐ１６表达的检测。结果：ｂｃｌ－２在膀胱癌的阳性表达率为８２４％（４２／５１）。在预后中生存组和死亡组之间比较有显著性差异（Ｐ＜００５）。Ｐ１６在膀胱癌的阳性表达率为５１０％（２６／５１）。５例正常膀胱粘膜均阳性，两者比较有显著性差异（Ｐ＜００５）。在病理分级、临床分期和预后的总样本率中比较有显著性差异（Ｐ＜００５）。即随病理分级临床分期的上升和预后的不良，Ｐ１６的阳性表达下降。ｂｃｌ－２阳性而Ｐ１６阴性（２０例）的分布也随病理分级，临床分期的上升和预后不良而上升（Ｐ＜００５）。ｂｃｌ－２和Ｐ１６都阳性（２２例）的分布，随病理分级临床分期升高和预后不良而下降（Ｐ＜００５）。结论：原癌基因ｂｃｌ－２的过度表达和抑癌基因Ｐ１６的缺失突变与膀胱癌的发生发展及预后有密切关系。可作为评估膀胱癌恶性程度及预后的指标。
Objective: To investigate the relationship between the expression of bcl-2 and P16 protein in bladder cancer and their clinicopathological significance and prognosis. Methods: The expressions of bcl-2 and P16 genes in 51 cases of bladder cancer and 5 cases of normal bladder mucosa were detected by immunohistochemical SABC method. Results: The positive rate of bcl-2 in bladder cancer was 82.4% (42/51). There was a significant difference between survival group and death group in prognosis (P <005). The positive rate of P16 in bladder cancer was 510% (26/51). Five cases of normal bladder mucosa were positive, the two were significantly different (P <0 05). There was a significant difference in the total sample rate of pathological grade, clinical stage and prognosis (P <005). That is, with the clinical stage of the pathological grade and poor prognosis, P16 positive expression decreased. The distribution of bcl-2 positive and P16 negative (20 cases) also increased with the pathological grade, clinical stage and poor prognosis (P <005). The positive expression of bcl-2 and P16 (22 cases) decreased with the increase of clinical stage and poor prognosis (P <005). Conclusion: The overexpression of the oncogene bcl-2 and the deletion mutation of the tumor suppressor gene P16 are closely related to the occurrence, development and prognosis of bladder cancer. Can be used as an indicator of malignancy and prognosis of bladder cancer.